Replimune Group, Inc. (REPL)
NASDAQ: REPL · IEX Real-Time Price · USD
7.15
+0.03 (0.42%)
At close: Apr 16, 2024, 4:00 PM
6.99
-0.16 (-2.24%)
After-hours: Apr 16, 2024, 6:24 PM EDT

Company Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.

The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.

Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells.

Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune Group, Inc.
Replimune Group logo
Country United States
Founded 2015
IPO Date Jul 20, 2018
Industry Biotechnology
Sector Healthcare
Employees 284
CEO Dr. Sushil Patel Ph.D.

Contact Details

Address:
500 Unicorn Park
Woburn, Massachusetts 01801
United States
Phone (781) 222-9600
Website replimune.com

Stock Details

Ticker Symbol REPL
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001737953
CUSIP Number 76029N106
ISIN Number US76029N1063
Employer ID 82-2082553
SIC Code 2836

Key Executives

Name Position
Philip Astley-Sparke F.S.A. Executive Chairman
Dr. Sushil Patel Ph.D. Chief Executive Officer
Dr. Robert Coffin Ph.D. Founder, Chief Scientist and Director
Emily Luisa Hill Chief Financial Officer
Andrew Schwendenman Chief Accounting Officer and Treasurer
Christopher Sarchi Chief Commercial Officer
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. Chief Medical Officer
Paul Bullock Chief Manufacturing Officer and Framingham Site Head

Latest SEC Filings

Date Type Title
Apr 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Apr 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 26, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 10-Q Quarterly Report
Feb 8, 2024 8-K Current Report